Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
COC · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| COC + Maridebart Cafraglutide | EXPERIMENTAL | Participants will receive COC orally and maridebart cafraglutide subcutaneously (SC). |
| Name | Type | Description |
|---|---|---|
| COC | DRUG | Administered orally. |
| Maridebart Cafraglutide | DRUG | Administered as SC injection. |
Inclusion Criteria 1. Participants must be postmenopausal females 45 to 65 years of age. Postmenopausal status must be confirmed based on the protocol-defined criteria. 2. Body mass index must be ≥ 25.0 and ≤ 38.0 kg/m\^2. 3. Body weight must be stable, with less than 5 kg self-reported change in t...
COC is an investigational small molecule being developed for the treatment of overweight. It is currently in Phase 1 clinical development. The drug is being studied in postmenopausal female participants living with overweight or obesity, according to the active clinical trial.
COC is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker AMGN. The company is conducting a Phase 1 clinical trial to evaluate the drug's effects in participants with overweight or obesity.
COC is in Phase 1 clinical development. The drug is being evaluated in an active but not recruiting clinical trial with 49 participants. It is an investigational drug and has not been approved by regulatory authorities.
COC is being studied in a Phase 1 clinical trial with the identifier NCT07523711. The trial is titled 'Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity' and is being conducted in the United States.
Yes, COC is the same as Maridebart Cafraglutide. The clinical trial NCT07523711 evaluates the effect of Maridebart Cafraglutide on oral contraceptives in postmenopausal female participants with overweight or obesity. This trial is the basis for the drug's development in the overweight indication.